Table 2 Characteristics of the patients from whom the tissue samples were obtained. All samples were at stage IV.
Patient | Agea | Mutations at CRC-related genesb | Sex | Diagnosis | Grade | Location | Chemotherapy |
|---|---|---|---|---|---|---|---|
CRC-PM 1c | 51 | KRAS G12D | Female | Mucinous Adenocarcinoma | G2 | Colon | Yes |
CRC-PM 2 | 47 | NONE | Female | Adenocarcinoma | G2 | Sigma | Yes |
CRC-PM 3 | 40 | NONE | Male | Adenocarcinoma | G2 | Colon | Yes |
CRC-PM 4 | 82 | ND | Female | Mucinous Adenocarcinoma | G3 | Right colon | No |
CRC-PM 5c | 66 | BRAF V600E | Female | Adenocarcinoma | G3 | Right colon | Yes |
CRC-PM 6 | 71 | KRAS G12S | Female | Adenocarcinoma | G3 | Colon | No |
CRC-PM 7 | 47 | NONE | Male | Mucinous Adenocarcinoma | G2 | Rectum | Yes |
CRC-PM 8 | 41 | KRAS G12S | Male | Mucinous adenocarcinoma | G3 | Sigma | Yes |
CRC-PM 9c | 43 | KRAS G12S | Female | Mucinous Adenocarcinoma | G2 | Right colon | Yes |
CRC-PM 10c | 60 | ND | Male | Adenocarcinoma | G3 | Colon | Yes |
CRC-PM 11c | 63 | NONE | Female | Mucinous Adenocarcinoma | G3 | Colon | Yes |
CRC-PM 12 | 65 | NONE | Female | Adenocarcinoma | G3 | Sigma | Yes |
CRC-PM 13 | 82 | # | Female | Colorectal neuroendocrine carcinoma | # | # | # |
CRC-PM 14 | 61 | BRAF V600E | Male | Adenocarcinoma | G2 | Colon | No |
